LUC00118I2 - - Google Patents

Download PDF

Info

Publication number
LUC00118I2
LUC00118I2 LU00118C LUC00118C LUC00118I2 LU C00118 I2 LUC00118 I2 LU C00118I2 LU 00118 C LU00118 C LU 00118C LU C00118 C LUC00118 C LU C00118C LU C00118 I2 LUC00118 I2 LU C00118I2
Authority
LU
Luxembourg
Application number
LU00118C
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00118(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of LUC00118I1 publication Critical patent/LUC00118I1/fr
Publication of LUC00118I2 publication Critical patent/LUC00118I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
LU00118C 2004-11-12 2019-05-08 LUC00118I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (fr) 2004-11-12 2005-11-14 Modification du facteur fviii en fonction du site

Publications (2)

Publication Number Publication Date
LUC00118I1 LUC00118I1 (fr) 2019-05-13
LUC00118I2 true LUC00118I2 (fr) 2019-12-27

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00118C LUC00118I2 (fr) 2004-11-12 2019-05-08

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP3243834A1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR101468345B1 (fr)
CN (6) CN103214569B (fr)
AU (1) AU2005304622B2 (fr)
BE (1) BE2019C523I2 (fr)
BR (2) BRPI0517795B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK2363414T3 (fr)
ES (4) ES2930143T3 (fr)
FR (1) FR19C1031I2 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20070268B1 (fr)
HU (5) HUE059193T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT2363414T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (3) MX2007005466A (fr)
NL (1) NL300989I2 (fr)
NO (3) NO20210454A1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352B1 (fr)
PL (3) PL2363414T3 (fr)
PT (4) PT2363414T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI3130601T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2571292C (fr) 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
EP3061461A1 (fr) 2004-10-29 2016-08-31 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
US20090252720A1 (en) * 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
DK2257311T3 (da) * 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
AU2009256093A1 (en) * 2008-06-04 2009-12-10 Bayer Healthcare Llc FVIII muteins for treatment of von Willebrand disease
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
JP5785872B2 (ja) * 2008-10-17 2015-09-30 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 低度の水溶性ポリマーを含む改変血液因子
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
WO2010060081A1 (fr) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Procédé de détermination d’activité de facteur de coagulation sanguine pégylé dans un essai de temps de thromboplastine partielle activée à base de silice
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP2012518029A (ja) * 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
SG174320A1 (en) * 2009-03-20 2011-10-28 Hanmi Holdings Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011012850A2 (fr) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glyco-polysialylation de protéines de coagulation non sanguine
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
WO2011069164A2 (fr) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Polypeptides chimériques et hybrides de facteur viii-fc, et procédés d'utilisation de ceux-ci
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
ES2769629T3 (es) * 2010-02-21 2020-06-26 Bayer Healthcare Llc Procedimiento de activación y conjugación de biomoléculas
ES2742216T3 (es) 2010-04-15 2020-02-13 Kodiak Sciences Inc Polímeros que contienen zwitteriones de alto peso molecular
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3508573A1 (fr) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
EP2651433A1 (fr) * 2010-12-16 2013-10-23 Novo Nordisk A/S Solution aqueuse de facteur viii
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP2714093A1 (fr) * 2011-05-27 2014-04-09 Baxter International Inc. Protéines thérapeutiques à plus longue demi-vie et leurs procédés de préparation
CA2838833A1 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composes pro-coagulants et leurs procedes d'utilisation
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
WO2013120939A1 (fr) 2012-02-15 2013-08-22 Csl Behring Gmbh Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
EP2822577B1 (fr) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2666782A1 (fr) 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (fr) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Procédé d'utilisation de polypeptide du facteur viii
JP2016518321A (ja) * 2013-03-15 2016-06-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組み換え因子ｖｉｉｉ配合物
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (fr) 2013-09-08 2015-03-12 Oligasis Llc Conjugués polymère zwittérionique-facteur viii
EA201690817A1 (ru) * 2013-10-22 2016-08-31 Дбв Текнолоджиз Способ лечения гемофилии индукцией толерантности к факторам крови
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP3082848B1 (fr) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Outils pharmacocinétiques de population et leurs utilisations
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
AU2015207472B2 (en) 2014-01-20 2018-11-22 Octapharma Ag A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag
EP3102589A1 (fr) 2014-02-04 2016-12-14 Biogen MA Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
EP3114138B1 (fr) 2014-03-05 2021-11-17 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
WO2015154090A1 (fr) * 2014-04-04 2015-10-08 Bloodworks Laboratoire ordinaire et analyse hors laboratoire de l'hémostase
EP3129463B1 (fr) 2014-04-10 2021-05-26 Bayer Healthcare LLC Formulation de poudre sèche et procédé pour preparer un milieu liquide de culture cellulaire
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2978374A1 (fr) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Facteur von willebrand modifie presentant une demi-vie amelioree
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
WO2018093766A1 (fr) 2016-11-16 2018-05-24 Bayer Healthcare Llc Facteur viii ciblé de globules rouges et son procédé d'utilisation
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018144623A1 (fr) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
WO2019219049A1 (fr) 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 Protéine de fusion du fviii améliorée et utilisation associée
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
WO2021113800A1 (fr) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions et procédés de modulation de la fonction du facteur viii

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (fr) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994007510A1 (fr) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
WO1994015625A1 (fr) 1993-01-15 1994-07-21 Enzon, Inc. Conjugues de polymere et de facteur viii
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0730660A4 (fr) 1993-10-29 1998-02-25 Incyte Pharma Inc Proteines chimeres contenant des variantes de la protease nexine-1
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (fr) 1994-11-09 1997-08-13 Robin Ewart Offord Polymeres fonctionnalises destines a une ligation dirigee
EP0776530A4 (fr) * 1995-06-21 1998-06-10 Motorola Inc Procede et antenne produisant un diagramme de rayonnement omnidirectionnel
WO1997003195A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues polypeptidiques de facteur viii:c ayant des sites de protease modifies
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
IL128229A0 (en) * 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
CA2306629A1 (fr) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
CA2329768C (fr) 1998-04-27 2008-06-10 Opperbas Holding B.V. Composition pharmaceutique a base de facteur viii et de liposomes neutres
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
WO2000071714A2 (fr) 1999-05-24 2000-11-30 The American National Red Cross Procedes de reduction de la clairance du facteur viii et compositions correspondantes
EP1982732A3 (fr) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Conjugués de type facteur VII ou VIIA
EP1319016A4 (fr) 2000-09-19 2006-05-10 Univ Emory Facteur viii modifie
EP1351986A2 (fr) 2001-01-12 2003-10-15 The American National Red Cross Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
IL157842A0 (en) * 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
WO2002098454A2 (fr) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
EP2110385A1 (fr) 2001-06-14 2009-10-21 The Scripps Research Institute Facteur VIII stabilisé doté de liens disulfure construits
ATE417618T1 (de) 2001-10-05 2009-01-15 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
WO2003087161A1 (fr) 2002-04-18 2003-10-23 Merck Patent Gmbh Facteur viii modifie
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
WO2004060966A2 (fr) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Derives polymeres d'acides maleamiques et leurs bioconjugues
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
WO2004075923A2 (fr) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Conjugues de groupe fonctionnel a facteur polymerique viii
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1626983B8 (fr) 2003-05-12 2010-12-22 Affymax, Inc. Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
WO2005046583A2 (fr) 2003-10-30 2005-05-26 Emory University Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006103298A2 (fr) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Analogues du fviii de coagulation sanguine
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
CY2019024I2 (el) 2019-11-27
DK1824988T3 (en) 2017-08-07
MA29663B1 (fr) 2008-08-01
LUC00118I1 (fr) 2019-05-13
CN101124331B (zh) 2013-04-24
HUE033776T2 (en) 2018-01-29
NZ555032A (en) 2010-02-26
RU2423380C2 (ru) 2011-07-10
UA95225C2 (ru) 2011-07-25
EP3323829B1 (fr) 2020-07-15
EP2363414A3 (fr) 2012-03-21
EP3243833A1 (fr) 2017-11-15
HUE059193T2 (hu) 2022-10-28
JP2015134780A (ja) 2015-07-27
HK1182121A1 (en) 2013-11-22
EP3153181A1 (fr) 2017-04-12
EP2772500A1 (fr) 2014-09-03
JP2013067621A (ja) 2013-04-18
HRP20070268A2 (en) 2007-09-30
PH12014500352A1 (en) 2015-07-20
LT2371856T (lt) 2022-08-25
CN107082806A (zh) 2017-08-22
EP1824988A4 (fr) 2008-12-31
US20130274445A1 (en) 2013-10-17
HUE060016T2 (hu) 2023-01-28
KR20070110260A (ko) 2007-11-16
CN103102406A (zh) 2013-05-15
EP2772500B1 (fr) 2019-12-25
KR20130036780A (ko) 2013-04-12
SI3130601T1 (sl) 2020-11-30
HRP20070268B1 (hr) 2018-04-20
US9096656B2 (en) 2015-08-04
FR19C1031I1 (fr) 2019-06-28
HUE050542T2 (hu) 2020-12-28
DK2363414T3 (da) 2022-08-08
KR20160105928A (ko) 2016-09-07
CN105148287A (zh) 2015-12-16
PL2363414T3 (pl) 2022-09-05
KR20140019489A (ko) 2014-02-14
EP2371856B1 (fr) 2022-05-18
EP3243834A1 (fr) 2017-11-15
LTPA2019509I1 (lt) 2019-08-26
MX2007005466A (es) 2007-10-19
CN101124331A (zh) 2008-02-13
CA2586379C (fr) 2012-04-03
HRP20180481A2 (hr) 2018-06-29
KR20120136413A (ko) 2012-12-18
ES2930143T3 (es) 2022-12-07
ES2821832T3 (es) 2021-04-27
JP2017105773A (ja) 2017-06-15
PT3130601T (pt) 2020-10-01
JP2017101028A (ja) 2017-06-08
NL300989I2 (nl) 2019-11-28
PT2371856T (pt) 2022-08-12
KR101654011B1 (ko) 2016-09-05
KR101468345B1 (ko) 2014-12-03
LT2363414T (lt) 2022-10-25
KR101483917B1 (ko) 2015-01-16
HN2007015683A (es) 2011-07-11
EP3243833B1 (fr) 2020-06-17
MX350293B (es) 2017-09-04
ES2930159T3 (es) 2022-12-07
HK1117875A1 (en) 2009-01-23
AU2005304622A1 (en) 2006-05-18
RU2007121517A (ru) 2008-12-20
US20160051633A1 (en) 2016-02-25
BRPI0517795B8 (pt) 2021-05-25
MX392760B (es) 2025-03-24
US7632921B2 (en) 2009-12-15
HK1218718A1 (zh) 2017-03-10
PL2371856T3 (pl) 2022-08-22
IL182903A0 (en) 2007-08-19
NO345800B1 (no) 2021-08-09
EP2371856A3 (fr) 2012-03-14
KR101904630B1 (ko) 2018-10-04
BRPI0517795B1 (pt) 2020-03-31
EP3130601A1 (fr) 2017-02-15
SI2371856T1 (sl) 2022-09-30
NO344606B1 (no) 2020-02-10
EP3323829A1 (fr) 2018-05-23
EP2371856A2 (fr) 2011-10-05
CY1119292T1 (el) 2018-02-14
EP1824988B1 (fr) 2017-04-19
JP6559642B2 (ja) 2019-08-14
AU2005304622B2 (en) 2012-03-29
KR20140091618A (ko) 2014-07-21
CN103102406B (zh) 2015-05-27
BRPI0517795A (pt) 2008-10-21
SI1824988T1 (sl) 2017-11-30
IL182903A (en) 2014-09-30
JP6018238B2 (ja) 2016-11-02
PH12014500352B1 (en) 2019-09-25
ZA200703696B (en) 2008-08-27
JP6487895B2 (ja) 2019-03-20
CN105148287B (zh) 2019-07-09
CY2019024I1 (el) 2019-11-27
BR122016022033B1 (pt) 2021-03-02
HUS1900026I1 (hu) 2022-04-28
PT2363414T (pt) 2022-08-04
HRP20180481B1 (hr) 2022-02-18
CN103214569B (zh) 2016-12-28
EP2363414A2 (fr) 2011-09-07
LTC1824988I2 (lt) 2021-02-25
ES2633916T3 (es) 2017-09-26
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
BE2019C523I2 (fr) 2025-02-10
BR122016022033B8 (pt) 2021-05-25
LT3130601T (lt) 2020-09-10
PT1824988T (pt) 2017-07-21
WO2006053299A3 (fr) 2006-08-24
CA2586379A1 (fr) 2006-05-18
IL232540A0 (en) 2014-06-30
PH12019501613A1 (en) 2020-09-14
EP1824988A2 (fr) 2007-08-29
US20060115876A1 (en) 2006-06-01
PL1824988T3 (pl) 2018-01-31
EP2363414B1 (fr) 2022-05-18
DK2371856T3 (en) 2022-08-08
LT1824988T (lt) 2017-10-25
IL232540A (en) 2017-08-31
WO2006053299A2 (fr) 2006-05-18
KR20180110192A (ko) 2018-10-08
EP3130601B1 (fr) 2020-07-15
US20100081615A1 (en) 2010-04-01
FR19C1031I2 (fr) 2020-06-05
JP2008524117A (ja) 2008-07-10
NO20200044A1 (no) 2007-06-27
CY1123384T1 (el) 2021-12-31
BRPI0517795A8 (pt) 2018-12-26
KR101243564B1 (ko) 2013-03-27
NL300989I1 (nl) 2019-05-22
IL234433B (en) 2019-11-28
CN103214569A (zh) 2013-07-24
NO20072997L (no) 2007-06-27
US9364520B2 (en) 2016-06-14
JP6109523B2 (ja) 2017-04-05
CN105753968A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
LUC00118I1 (fr)
BE2016C020I2 (fr)
FR14C0003I1 (fr)
JP2004308660A5 (fr)
JP2005271135A5 (fr)
DE602005020607D1 (fr)
BR122018073034B8 (fr)
ECSDI045510S (fr)
JP2005262469A5 (fr)
JP2005238697A5 (fr)
CN301067823S (zh) 促销用装置
CN300742588S (zh) 洗手盆
FR2848611A3 (fr)
FR2846125A3 (fr)
ECSDI045023S (fr)
FR2849623A3 (fr)
FR2846363A3 (fr)
FR2850603A3 (fr)
FR2841545A3 (fr)
CN3398149S (fr)
CN3374665S (fr)
CN3383291S (fr)
CN3357601S (fr)
CN3389119S (fr)
CN3403587S (fr)